113 related articles for article (PubMed ID: 8932835)
21. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
22. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Zwaveling J; den Hartigh J; Lankester AC; Guchelaar HJ; Egeler RM; Bredius RG
Anticancer Drugs; 2006 Oct; 17(9):1099-105. PubMed ID: 17001185
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation.
Schechter T; Finkelstein Y; Doyle J; Verjee Z; Moretti M; Koren G; Dupuis LL
Biol Blood Marrow Transplant; 2007 Mar; 13(3):307-14. PubMed ID: 17317584
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and individualized dose adjustment of intravenous busulfan in children with advanced hematologic malignancies undergoing allogeneic stem cell transplantation.
Tran H; Petropoulos D; Worth L; Mullen CA; Madden T; Andersson B; Choroszy M; Nguyen J; Webb SK; Chan KW
Biol Blood Marrow Transplant; 2004 Nov; 10(11):805-12. PubMed ID: 15505611
[TBL] [Abstract][Full Text] [Related]
25. Urinary excretion and pharmacokinetics of acrolein and its parent drug cyclophosphamide in bone marrow transplant patients.
Al-Rawithi S; El-Yazigi A; Ernst P; Al-Fiar F; Nicholls PJ
Bone Marrow Transplant; 1998 Sep; 22(5):485-90. PubMed ID: 9733272
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation.
Balasubramanian P; Chandy M; Krishnamoorthy R; Srivastava A
Bone Marrow Transplant; 2001 Nov; 28(9):821-5. PubMed ID: 11781641
[TBL] [Abstract][Full Text] [Related]
27. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation.
Schuler US; Renner UD; Kroschinsky F; Johne C; Jenke A; Naumann R; Bornhäuser M; Deeg HJ; Ehninger G
Br J Haematol; 2001 Sep; 114(4):944-50. PubMed ID: 11564090
[TBL] [Abstract][Full Text] [Related]
28. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
29. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfan-based preparative regimen for allogeneic haematopoietic SCT.
Główka FK; Karaźniewicz-Łada M; Grund G; Wróbel T; Wachowiak J
Bone Marrow Transplant; 2008 Oct; 42 Suppl 2():S67-70. PubMed ID: 18978748
[TBL] [Abstract][Full Text] [Related]
31. Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.
Faraci M; Tinelli C; Lanino E; Giardino S; Leoni M; Ferretti M; Castagnola E; Broglia M; De Silvestri A; Di Martino D; Bartoli A
Eur J Drug Metab Pharmacokinet; 2018 Apr; 43(2):173-181. PubMed ID: 28801891
[TBL] [Abstract][Full Text] [Related]
32. Individualized population pharmacokinetic model with limited sampling for cyclosporine monitoring after liver transplantation in clinical practice.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; Hommes DW; van Hoek B
Aliment Pharmacol Ther; 2007 Nov; 26(10):1447-54. PubMed ID: 17848182
[TBL] [Abstract][Full Text] [Related]
33. Fractionated TBI correlates with less T cell mixed chimerism but increased risk of relapse compared to busulphan in patients with haematological malignancies after allogeneic stem cell transplantation.
Mattsson J; Uzunel M; Remberger M; Hassan M
Bone Marrow Transplant; 2003 Sep; 32(5):477-83. PubMed ID: 12942093
[TBL] [Abstract][Full Text] [Related]
34. Intraindividual variability in busulfan pharmacokinetics in patients undergoing a bone marrow transplant: assessment of a test dose and first dose strategy.
Lindley C; Shea T; McCune J; Shord S; Decker J; Harvey D; Petros WP; Garbriel D; Serody J; Kirby S; Wiley J
Anticancer Drugs; 2004 Jun; 15(5):453-9. PubMed ID: 15166618
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus clearance is age-dependent within the pediatric population.
Przepiorka D; Blamble D; Hilsenbeck S; Danielson M; Krance R; Chan KW
Bone Marrow Transplant; 2000 Sep; 26(6):601-5. PubMed ID: 11041564
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic bone marrow transplantation for children with acute leukemia: long-term follow-up of patients prepared with high-dose cytosine arabinoside and fractionated total body irradiation.
Gordon BG; Warkentin PI; Strandjord SE; Abromowitch M; Bayever E; Harper JL; Coccia PF
Bone Marrow Transplant; 1997 Jul; 20(1):5-10. PubMed ID: 9232249
[TBL] [Abstract][Full Text] [Related]
37. Busulfan pharmacokinetics do not predict relapse in acute myeloid leukemia.
Baker KS; Bostrom B; DeFor T; Ramsay NK; Woods WG; Blazar BR
Bone Marrow Transplant; 2000 Sep; 26(6):607-14. PubMed ID: 11041565
[TBL] [Abstract][Full Text] [Related]
38. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies.
Dupuis LL; Sibbald C; Schechter T; Ansari M; Gassas A; Théorêt Y; Kassir N; Champagne MA; Doyle J
Biol Blood Marrow Transplant; 2008 May; 14(5):576-82. PubMed ID: 18410900
[TBL] [Abstract][Full Text] [Related]
39. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients.
Ljungman P; Hassan M; Békássy AN; Ringdén O; Oberg G
Bone Marrow Transplant; 1997 Dec; 20(11):909-13. PubMed ID: 9422468
[TBL] [Abstract][Full Text] [Related]
40. Cyclosporine A (CsA) 2-h concentrations vary between patients without correlation to graft-versus-host disease after allogeneic haematopoietic stem cell transplantation.
Barkholt L; Remberger M; Bodegård H; Ringdén O; Böttiger Y
Bone Marrow Transplant; 2007 Oct; 40(7):683-9. PubMed ID: 17660840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]